Navigation Links
Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
Date:5/7/2012

NEW YORK, May 7, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Yale University.

"In the course of research conducted under Yale auspices, Dr. Kevan Herold and his colleagues at Yale University School of Medicine have developed a technology entitled 'Circulating hypomethylated B cell-derived DNA' as a biomarker of B cell destruction," said John Steel, Chairman and CEO of Islet Sciences. "We are excited to utilize this groundbreaking invention as we look to commercialize it to benefit the growing worldwide diabetic community. This test has the potential to identify beta cell death and emerging diabetes far earlier than clinical presentation."

"The opportunity to identify diabetes and islet dysfunction prior to clinical presentation could be beneficial therapeutically," said Dr. Kevan Herold. "I am looking forward to working with Islet Sciences to commercialize this technology that clearly holds so much potential."

Clusters of beta cells form islets within the pancreas. Diminished beta/islet cell function which can be caused by numerous factors, is one of the primary causes of insulin dependent diabetes. Insulin dependent diabetes is the more difficult aspect of the disease.

Jonathan Soderstrom, director of the Office of Cooperative Research at Yale commented, "We are pleased that Islet Sciences has made the decision to invest in this discovery and look forward to developing it into a valuable new tool for treating this debilitating disease."

About Islet Sciences, Inc.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes. The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace. www.isletsciences.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson
ProActive Capital Resources Group
(646) 863-6893
jramson@proactivecrg.com


'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
2. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
3. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2020)... ... January 22, 2020 , ... ... technical services exclusively to the healthcare industry, announced today that Southern Illinois ... automation program for its Epic EHR. SIH is a prominent multi-hospital health system ...
(Date:1/12/2020)... , ... January 10, 2020 ... ... that Founder and CEO Remo Moomiaie-Qajar, MD has been selected to present ... company that has developed a vast platform with its proprietary Cargocyte™ next ...
(Date:1/12/2020)... ... January 12, 2020 , ... FutuRx, Israel’s leading ... JJDC, and Takeda Ventures, Inc, operating under a tender from the Israeli Innovation ... collaboration with Ramot at Tel-Aviv University and Glasgow University. , Epeius pharma ...
Breaking Medicine Technology:
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... global consulting firm for the life sciences and food industries, is pleased to ... Specialist, at their head office and research site in Toronto, Canada. , Dr. ...
(Date:1/23/2020)... ... January 23, 2020 , ... A January 7 ... to get rid of them. The article quotes the president of the American Society ... are many. They can be caused by a person’s facial structure including an undefined ...
(Date:1/23/2020)... ... , ... Let’s face it; the holidays were a stressful time, a time ... secrets were revisited. It’s easy to understand why many folks prefer to duck out ... the holidays posed additional stress for which there is no “cookie-cutter” solution. , Dylan ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... Park Avenue ... new website jschildhorn.com. Dr. Schildhorn is excited to bring this new digital portal for ... of Duke and attended medical school at Temple University. With over 12 years of ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... SaaS vendor announced their partner agreement with Healthpac, a trusted medical billing ... offices and medical offices an expanded offering. Healthpac’s customers can now access ...
Breaking Medicine News(10 mins):